Allosteric modulators of CB1 cannabinoid receptors
AssigneeNortheastern University
InventorsGaneshsingh A. Thakur, Pushkar M. Kulkarni
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
Claims3
A pharmaceutical composition for treatment of Huntington's disease, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
- and a pharmaceutically-acceptable carrier or diluent.
A pharmaceutical composition for treatment of Huntington's disease or glaucoma, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
- and a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition for treatment of Huntington's disease, pain, neuropathic pain, glaucoma, post-traumatic stress disorder, or epileptic seizure, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
- and a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.